SCHEMBL3006901

SCHEMBL3006901

Cc1ccc(S(=O)(=O)C2CCN(c3nc(Cc4cc(F)cc(Cl)c4)cs3)CC2)cc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GBA1 P04062 1/20 0.39
HTR2A P28223 2/20 0.37
HTR2C P28335 2/20 0.37
KCNH2 Q12809 2/20 0.37
DRD2 P14416 1/20 0.37
SMN1; SMN2 Q16637 4/20 0.37
MAPT P10636 3/20 0.37
ALDH1A1 P00352 2/20 0.37
CYP1A2 P05177 1/20 0.37
POLB P06746 1/20 0.37
CYP2C9 P11712 1/20 0.37
HPGD P15428 1/20 0.37
CYP2C19 P33261 1/20 0.37
HTT P42858 1/20 0.37
KMT2A Q03164 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
DNM1L O00429 4/20 0.35
LMNA P02545 1/20 0.35
NPC1 O15118 1/20 0.35
RAB9A P51151 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3013097 0.94 GBA1 (0.42) GBA1HTR2AHTR2CKCNH2DRD2
SCHEMBL3011143 0.94 HTR2A (0.43) HTR2AHTR2CKCNH2DRD2SMN1; SMN2
SCHEMBL3012543 0.94 HTR2A (0.41) HTR2AHTR2CKCNH2DRD2SMN1; SMN2
SCHEMBL3013102 0.94 GBA1 (0.41) GBA1HTR2AHTR2CKCNH2DRD2
SCHEMBL3019381 0.91 HTR2A (0.37) HTR2AHTR2CKCNH2DRD2SMN1; SMN2
SCHEMBL3008584 0.91 DRD2 (0.34) HTR2AHTR2CKCNH2DRD2SMN1; SMN2
SCHEMBL3022162 0.91 HTR2A (0.42) HTR2AHTR2CKCNH2DRD2SMN1; SMN2
SCHEMBL3005733 0.91 HTR2A (0.35) HTR2AHTR2CKCNH2DRD2SMN1; SMN2
SCHEMBL3009811 0.90 HTR2A (0.36) HTR2AHTR2CKCNH2DRD2SMN1; SMN2
SCHEMBL3015772 0.90 HTR2A (0.44) HTR2AHTR2CKCNH2DRD2SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA GBA1 4/4885HTR2A 752/4885HTR2C 1153/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.